Compare Agilent Technologies Inc (A) vs CAVA Group Inc (CAVA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Agilent Technologies Inc vs CAVA Group Inc — how do they compare? Agilent Technologies Inc trades at $128.83 (market cap $37.04B), while CAVA Group Inc trades at $67.38 (market cap $8.12B). The key difference: Agilent Technologies Inc is far larger — about 4.6× CAVA Group Inc's market cap, and Agilent Technologies Inc pays a 0.78% dividend while CAVA Group Inc pays none. Which is the better fit depends on your goals.
| A | CAVA | |
|---|---|---|
Market Cap | $37.04B | $8.12B |
Sector | Health | Consumer Cyclical |
52-Week High | $157.20 | $97.39 |
52-Week Low | $110.24 | $43.59 |
Enterprise Value | $38.59B | $8.22B |
Dividend Yield | 0.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
CAVA stock is trading at $71.91, down 6.46% with a bearish technical signal. The company shows strong revenue growth reaching $1.18 billion in 2025 with positive net income of $63.74 million, though valuation metrics remain elevated with a P/E of 138.29. Recent earnings beat expectations in Q1 2026 with $0.20 EPS versus $0.17 expected. Analyst sentiment remains strongly positive with 72% buy ratings and a $94.19 consensus price target, representing 31% upside potential from current levels.
The outlook remains favorable given CAVA's expansion trajectory and market share gains in the fast-casual segment, though high valuation multiples and margin pressures present risks. The stock's recent pullback offers potential entry point for growth investors, but requires monitoring of same-store sales trends and competitive dynamics in the restaurant industry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About CAVA Group Inc
CAVA is a Mediterranean fast-casual restaurant brand in the US. It offers customizable bowls, salads, and pitas featuring healthy ingredients, while also selling its signature dips and dressings in grocery stores.
Read more on CAVA →
